RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
OncoTherapy Science Stock

OncoTherapy Science Equity 2024

OncoTherapy Science Equity

353.67 M JPY

Ticker

4564.T

ISIN

JP3202150003

WKN

726692

In 2024, OncoTherapy Science's equity was 353.67 M JPY, a -82.14% increase from the 1.98 B JPY equity in the previous year.

OncoTherapy Science Aktienanalyse

What does OncoTherapy Science do?

OncoTherapy Science Inc is a rising company that focuses on the research and development of novel cancer therapies. The company takes pride in being able to combine the latest scientific findings with cutting-edge technologies to develop highly effective drugs and therapies that can improve the lives of cancer patients. The company is based in Japan and was founded in 2001. Since its inception, it has become one of the leading companies in cancer research and its products are available worldwide. OncoTherapy Science Inc's business model is based on the development and commercialization of new innovative cancer therapies. The company utilizes the latest technologies and research findings to achieve groundbreaking advancements in cancer treatment. These innovative therapies have the potential to improve the survival and quality of life of cancer patients. OncoTherapy Science Inc divides its activities into various areas. This includes the research and development of drugs, the clinical testing of new therapies, and the production and commercialization of cancer therapies. The research and development of new drugs form the core of OncoTherapy Science Inc's activities. The company continuously invests in researching new treatment approaches to improve the effectiveness and safety of cancer therapies. Advanced technologies such as genome sequencing and molecular diagnostics are utilized to develop personalized therapies tailored to specific types of cancer and patients. OncoTherapy Science Inc also conducts extensive clinical trials to evaluate the effectiveness and safety of its therapies. The success rate of clinical studies is very high, and many of the therapies have already received approval from regulatory authorities. Another important area of OncoTherapy Science Inc is the production and commercialization of cancer therapies. The company works closely with its distribution partners to ensure that its products are available in many countries and regions. OncoTherapy Science Inc's therapies are recommended by many oncologists and used in leading clinical institutions worldwide. Products of OncoTherapy Science Inc include a range of innovative cancer therapies. These include antibody-based drugs, immunotherapies, RNA-based therapies, and chemotherapy. These therapies have the potential to improve the effectiveness of cancer treatment and enhance the quality of life of cancer patients. An example of an innovative therapy by OncoTherapy Science Inc is OTS964, a new chemotherapeutic agent for the treatment of pancreatic cancer and other cancers. OTS964 inhibits the enzyme TOPK, which is overexpressed in many types of cancer, leading to the death of cancer cells. This therapy has shown promising results in animal models and is currently being tested in clinical trials. OncoTherapy Science Inc aims to contribute to improving the quality of life of cancer patients. The company relies on a combination of innovative research, state-of-the-art technology, and close collaboration with other industry stakeholders to achieve a leading position in cancer research. With its strong market position and commitment to cancer research, OncoTherapy Science Inc is a company that will achieve much in the future. OncoTherapy Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing OncoTherapy Science's Equity

OncoTherapy Science's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding OncoTherapy Science's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating OncoTherapy Science's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

OncoTherapy Science's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in OncoTherapy Science’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about OncoTherapy Science stock

What is the equity of OncoTherapy Science this year?

OncoTherapy Science has equity of 353.67 M JPY this year.

What was the equity of OncoTherapy Science compared to the previous year?

The equity of OncoTherapy Science has increased/decreased by -82.14% decreased compared to the previous year.

What impact does a high equity have on investors of OncoTherapy Science?

A high equity is advantageous for investors of OncoTherapy Science as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of OncoTherapy Science?

A low equity can be a risk for investors of OncoTherapy Science, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of OncoTherapy Science affect the company?

An increase in equity of OncoTherapy Science can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of OncoTherapy Science affect the company?

A reduction in equity of OncoTherapy Science can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of OncoTherapy Science?

Some factors that can affect the equity of OncoTherapy Science include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of OncoTherapy Science so important for investors?

The equity of OncoTherapy Science is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can OncoTherapy Science take to change the equity?

To change equity, OncoTherapy Science can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does OncoTherapy Science pay?

Over the past 12 months, OncoTherapy Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoTherapy Science is expected to pay a dividend of 0 JPY.

What is the dividend yield of OncoTherapy Science?

The current dividend yield of OncoTherapy Science is .

When does OncoTherapy Science pay dividends?

OncoTherapy Science pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OncoTherapy Science?

OncoTherapy Science paid dividends every year for the past 0 years.

What is the dividend of OncoTherapy Science?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is OncoTherapy Science located?

OncoTherapy Science is assigned to the 'Health' sector.

Wann musste ich die Aktien von OncoTherapy Science kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OncoTherapy Science from 8/18/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 8/18/2024.

When did OncoTherapy Science pay the last dividend?

The last dividend was paid out on 8/18/2024.

What was the dividend of OncoTherapy Science in the year 2023?

In the year 2023, OncoTherapy Science distributed 0 JPY as dividends.

In which currency does OncoTherapy Science pay out the dividend?

The dividends of OncoTherapy Science are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von OncoTherapy Science

Our stock analysis for OncoTherapy Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoTherapy Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.